Fargen Kyle M, Midtlien Jackson P, Belanger Katherine, Hepworth Edward J, Hui Ferdinand K
Departments of Neurological Surgery and Radiology, Wake Forest University, Winston-Salem , North Carolina , USA.
Division of Otolaryngology, Skull Base, Head & Neck Surgery, Sinus Solutions at Veros Clinical Services, Denver , Colorado , USA.
Neurosurgery. 2024 Aug 1;95(2):400-407. doi: 10.1227/neu.0000000000002891. Epub 2024 Mar 13.
Cerebral venous outflow disorders (CVDs) secondary to internal jugular vein (IJV) stenosis are becoming an increasingly recognized cause of significant cognitive and functional impairment in patients. There are little published data on IJV stenting for this condition. This study aims to report on procedural success.
A single-center retrospective analysis was performed on patients with CVD that underwent IJV stenting procedures.
From 2019 to 2023, 29 patients with CVD underwent a total of 33 IJV stenting procedures. Most patients (20; 69%) had an underlying connective tissue disorder diagnosis. The mean age of the included patients was 36.3 years (SD 12.4), 24 were female (82.8%), and all were Caucasian except for 2 patients (27; 93.0%). Twenty-eight procedures (85%) involved isolated IJV stenting under conscious sedation, whereas 5 procedures (15%) involved IJV stenting and concomitant transverse sinus stenting under general anesthesia. Thirteen (39%) patients underwent IJV stenting after open IJV decompression and styloidectomy. Three patients had stents placed for stenosis below the C1 tubercle, one of which was for carotid compression. Periprocedural complications occurred in 11 (33%), including intracardiac stent migration in 1 patient, temporary shoulder pain/weakness in 5 (15%), and persistent and severe shoulder pain/weakness in 2 patients (6%). Approximately 75% of patients demonstrated improvement after stenting although only 12 patients (36%) had durable improvement over a mean follow-up of 4.5 months (range 6 weeks-3.5 years).
Our experience, along with early published studies, suggests that there is significant promise to IJV revascularization techniques in these patients; however, stenting carries a high complication rate, and symptom recurrence is common. Most neurointerventionalists should not be performing IJV stenting unless they have experience with these patients and understand technical nuances (stent sizing, anatomy, patient selection), which can maximize benefit and minimize risk.
继发于颈内静脉(IJV)狭窄的脑静脉流出道疾病(CVDs)正日益被认为是患者出现严重认知和功能障碍的原因。关于针对这种情况进行IJV支架置入术的已发表数据很少。本研究旨在报告手术成功率。
对接受IJV支架置入术的CVD患者进行单中心回顾性分析。
2019年至2023年,29例CVD患者共接受了33次IJV支架置入术。大多数患者(20例;69%)有潜在的结缔组织疾病诊断。纳入患者的平均年龄为36.3岁(标准差12.4),24例为女性(82.8%),除2例患者(27例;93.0%)外均为白种人。28例手术(85%)涉及在清醒镇静下单独进行IJV支架置入,而5例手术(15%)涉及在全身麻醉下进行IJV支架置入并同时进行横窦支架置入。13例(39%)患者在开放性IJV减压和茎突切除术后接受IJV支架置入。3例患者因C1结节以下狭窄置入支架,其中1例是因颈动脉受压。围手术期并发症发生在11例(33%),包括1例患者发生心内支架移位,5例(15%)出现短暂性肩部疼痛/无力,2例患者(6%)出现持续性严重肩部疼痛/无力。尽管平均随访4.5个月(范围6周 - 3.5年)仅有12例患者(36%)有持久改善,但约75%的患者在支架置入后症状有所改善。
我们的经验以及早期发表的研究表明,IJV血管重建技术在这些患者中有很大前景;然而,支架置入术并发症发生率高,症状复发很常见。大多数神经介入医生不应进行IJV支架置入术,除非他们有处理这些患者的经验并了解技术细节(支架尺寸、解剖结构、患者选择),这样才能使获益最大化并将风险最小化。